How SynergyRx prices care, who provides it, and where the product copy breaks down
SynergyRx is the current consumer brand for a broad cash-pay telehealth catalog. Its terms describe SynergyRx as a Delaware corporation at a Casper, Wyoming mailing address and repeatedly call the platform CareGLP. SynergyRx provides administrative and technology services rather than practicing medicine or operating the dispensing pharmacy.
The medical-service identity needs clarification. The current homepage names Lion MD and identifies Ana Lisa Carr, MD, and Kelly Tenbrink, MD, as physician leaders. The legal footer separately says medical services are provided through independent providers and Usable Health, PC. The site does not explain whether Lion MD and Usable Health serve different products, states, or parts of the same professional network.
Both physician NPIs are active in the federal NPI Registry. Dr. Carr's record lists family medicine and a California license, while Dr. Tenbrink's record lists emergency medicine and a Tennessee license. Those records verify identity, not assignment. A patient should still obtain the actual clinician's name, professional entity, role, and active license for the patient's state.
SynergyRx names Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx on its homepage. That is helpful, but no page maps one pharmacy to a specific medication, state, or formulation. Product notes say secondary pharmacies may serve some states and that cost can vary. Confirm the pharmacy before the prescription is filled.
The visible weight-loss cards list compounded semaglutide injection at $199 monthly and compounded tirzepatide injection at $349. They also list compounded dissolving-tablet variants at $299 and $399. Product descriptions say consultation, medication, and shipping are included for the main injections, but no public concentration, titration table, or statement that every dose costs the same was found.
The live product configuration contains longer-plan totals that the public card does not display. Semaglutide injection is configured at $748 for three months, $1,248 for six months, and $2,298 for twelve. Tirzepatide injection is $1,068, $1,898, and $3,498 for the same terms. The compact cards show the twelve-month equivalents of $192 and $292, while the notes preserve every exact total.
The plan table has unusual economics. Three months of semaglutide averages about $249 monthly, above the $199 one-month price. Three months of tirzepatide averages $356, above the $349 one-month price. That could reflect different quantities, service bundles, or stale configuration. SynergyRx does not explain the difference, so the checkout description and amount due should control.
Compounded semaglutide and tirzepatide dissolving tablets are route variants, not new active ingredients. They stay in the editorial notes instead of creating extra therapy cards. SynergyRx describes them as sublingual formulations, but they are not FDA-approved finished products equivalent to approved injections or oral tablets. The pharmacy, ingredient form, absorption data, dose, and monitoring plan matter.
The branded catalog lists Wegovy and Mounjaro at $947 monthly and Ozempic at $499. Wegovy has a chronic-weight-management indication. Current Mounjaro and Ozempic labels do not, so prescribing either solely for weight loss is off label. That distinction affects appropriate counseling and prevents all three prices from being treated as interchangeable obesity-drug offers.
The Ozempic description contains a material dose error. It lists a range through 2.4 mg, while the current Ozempic label lists a maximum of 2 mg weekly. The 2.4 mg dose is associated with Wegovy. A patient should rely on the current label, pharmacy package, and prescriber's written instructions rather than that product card.
The sexual-health catalog includes commercial tablets and compounded sublingual presentations of sildenafil and tadalafil, each at $109 monthly. Those presentations are consolidated under the two canonical active ingredients. The cards stay outside direct price ranking because SynergyRx does not publish the strength, tablet or dose count, use schedule, or whether the same $109 applies to every presentation.
The product named PT-141 is not comparison-ready. Its public description repeats sermorelin-style language about increasing growth hormone and lists anti-aging benefits. PT-141 is bremelanotide, a melanocortin receptor agonist whose approved finished-product indication is narrowly defined HSDD in selected premenopausal women. Until SynergyRx corrects the ingredient, indication, dose, and instructions, the $275 offer stays editorial-only.
NAD+ and sermorelin each cost $275 for the shortest option, $525 for three months, $899 for six months, or $1,599 for twelve. The annual equivalent is about $133 per month. SynergyRx also lists glutathione injection at $275 monthly and methylcobalamin B12 at $109. No product page publishes a complete vial quantity, injection schedule, monitoring plan, or included supply list.
NAD+ is biologically important, but that fact does not prove SynergyRx's marketed energy or longevity outcomes. FDA has received adverse-event reports after compounded NAD+ injectables and has warned compounders to use ingredients suitable for sterile drug production. Patients should confirm pharmaceutical-grade input, pharmacy identity, route, concentration, sterility controls, storage, and a measurable clinical goal.
Sermorelin is marketed for body composition, sleep, skin, and anti-aging goals. FDA review records say the former Geref approvals were withdrawn after production ended. Those former approvals do not create a current approved adult-longevity indication. The current SynergyRx offer should be treated as a compounded prescription requiring an individualized rationale, monitoring plan, and realistic outcome discussion.
Hair and skin products are deliberately not expanded into many new therapy cards. The four hair formulas combine minoxidil, finasteride, ketoconazole, or latanoprost under branded bundle names at $109. Six $119 skin creams combine ingredients such as tretinoin, hydroquinone, estriol, azelaic acid, or corticosteroids. The bundle price cannot be assigned cleanly to one ingredient, and several strength strings or names on the public page contain errors.
The onboarding sequence is straightforward. A patient completes a health questionnaire, meets with a licensed clinician, receives a treatment decision, and has medication shipped when prescribed. SynergyRx says refills involve monthly or quarterly progress review and dose adjustment. A prescription is not guaranteed, and the site does not publish one service-level timeline for every product.
The homepage advertises telemedicine in all fifty states, subject to state rules and provider availability. Product descriptions still list no-ship states for several sexual-health, hair, skin, and longevity preparations, or say a secondary pharmacy may change the cost. Availability should therefore be checked by medication, formulation, pharmacy, and state rather than inferred from the broad homepage claim.
Shipping is marketed as fast, free, discreet, and sometimes expedited. The four named pharmacies provide more context than an anonymous network, but the public pages do not publish one guaranteed processing window, carrier-delay process, cold-chain standard, temperature-excursion rule, replacement deadline, or state-by-state pharmacy assignment. Inspect the package promptly and obtain written storage instructions.
Support is advertised as available around the clock with unlimited appointments and messaging. Public routes include portal messaging, info@synergyrx.co, and a contact form. No general support telephone number or response-time commitment was found. The site also does not distinguish clearly between administrative support and an on-call licensed clinician.
Refund language conflicts. The about page advertises a money-back guarantee without conditions. The terms say medical consultation fees are nonrefundable, prescriptions cannot be returned for reuse or resale, and all sales are final. No public cancellation cutoff, renewal cancellation procedure, clinical-disqualification refund sequence, or multi-month-plan exit rule was found. The legal terms should be treated as controlling unless SynergyRx provides a written exception.
SynergyRx advertises a $100 welcome credit applied at checkout with no code. Complete eligibility, expiration, plan, and stacking rules are not public, so the CTA disclosure tells readers to confirm the credit before authorizing payment. The terms describe medical groups as out of network, warn that prescriptions and labs may not be covered, and do not publish a universal laboratory schedule despite HSA and FSA eligibility marketing.
- The lowest compact prices require twelve-month plans: about $192 for semaglutide, $292 for tirzepatide, and $133 for NAD+ or sermorelin.
- Money-back marketing conflicts with all-sales-final terms, and the public pages do not explain cancellation or renewal procedures.
- An incorrect Ozempic dose range and a PT-141 description copied from sermorelin are material reasons to verify every medication against the prescription and pharmacy label.
